Abstract:Recombinant adeno-associated virus (rAAV) platforms hold promise for in vivo gene therapy but are undermined by the undesirable transduction of antigen presenting cells (APCs), which in turn can trigger host immunity towards rAAV-expressed transgene products. In light of recent adverse events in patients receiving high systemic AAV vector doses that were speculated to be related to host immune responses, development of strategies to mute innate and adaptive immunity is imperative. The use of miRNA binding sites (miR-BSs) to confer endogenous miRNA-mediated regulation to detarget transgene expression from APCs has shown promise for reducing transgene immunity. Studies have shown that designing miR-142BSs into rAAV1 vectors were able to repress costimulatory signals in dendritic cells (DCs), blunt the cytotoxic T cell response, and attenuate clearance of transduced muscle cells in mice to allow sustained transgene expression in myofibers with negligible anti-transgene IgG production. In this study, we screened individual and combinatorial miR-BS designs against 26 miRNAs that are abundantly expressed in APCs, but not in skeletal muscle. The highly immunogenic ovalbumin (OVA) transgene was used as a proxy for foreign antigens. In vitro screening in myoblasts, mouse DCs, and macrophages revealed that the combination of miR-142BS and miR-652-5pBS strongly mutes transgene expression in APCs but maintains high myoblast and myocyte expression. Importantly, rAAV1 vectors carrying this novel miR-142/652-5pBS cassette achieve higher transgene levels following intramuscular injections in mice than previous detargeting designs. The cassette strongly inhibits cytotoxic CTL activation and suppresses the Th17 response in vivo . Our approach, thus, advances the efficiency of miRNA-mediated detargeting to achieve synergistic reduction of transgene-specific immune responses and the development of safe and efficient delivery vehicles for gene therapy.

Trans-amplifying RNA expressing functional miRNA mediates target-specific gene suppression and simultaneous transgene expression

TALEN/CRISPR-mediated Engineering of a Promoterless Anti-Viral RNAi Hairpin into an Endogenous Mirna Locus

Bicistronic gene transfer tools for delivery of miRNAs and protein coding sequences

Transcripts for Combined Synthetic Microrna and Gene Delivery

Application of Microrna-Mediated Mechanism of Transgene Expression Systems in Viral Vaccine Development

Broad-spectrum immune suppression encoded in self-amplifying RNA enables non-cytotoxic, non-immunostimulatory, reversible transgene expression

A Sendai Virus-Based Cytoplasmic RNA Vector as a Novel Platform for Long-Term Expression of MicroRNAs

A Lentiviral Microrna-Based System for Single-Copy Polymerase II-regulated RNA Interference in Mammalian Cells

Progress in Microrna Delivery

Efficient Inhibition of HIV-1 Replication by an Artificial Polycistronic Mirna Construct

miRNA circuit modules for precise, tunable control of gene expression

Lentivirus-mediated Long-Term Overexpression of Specific Microrna for Complementary Mirna Pairs in Mammalian Cells

Artificial miRNAs are potential gene therapy tools, especially for incurable monogenic disorders

Effective and Accurate Gene Silencing by a Recombinant AAV-Compatible MicroRNA Scaffold.

Rna Interference: A Potent Tool for Gene-Specific Therapeutics

Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cells

Advances in research of microRNA-mediated gene engineering attenuated strain of virus

A Small Molecule Enhances RNA Interference and Promotes Microrna Processing

SY-9 Stimulation of Innate Immunity by Short Interfering and Micro RNAs

Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction

Synthetic Messenger RNA As a Tool for Gene Therapy